RxDoctor Payments Data

Mary Schmitz

Physician Assistant · Litchfield Park, AZNPI 1639764145

Payments from drug & device makers

$2,586in general payments, 2019–2025

Across 112 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$472
  • Johnson & Johnson$422
  • Merck$184
  • Endo USA, Inc.$176
  • Sumitomo Pharma America, Inc.$121
  • Endo Pharmaceuticals Inc.$120
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,51897%
  • Education$683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,586 in reported general payments places this provider in the 80th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$133,273
Medicare patients
653
Services billed
7,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron113$104,870
GemtesaVibegron84$71,503
Estradiol345$23,048
Trospium Chloride163$10,120
Potassium Citrate ErPotassium Citrate59$9,185
Tamsulosin Hcl535$8,009
Solifenacin Succinate118$5,847
Fesoterodine Fumarate ErFesoterodine Fumarate13$3,465
Finasteride192$2,823
Testosterone Cypionate56$2,482
Trospium Chloride ErTrospium Chloride12$2,122
Methenamine Hippurate18$1,755
Oxybutynin Chloride26$1,209
Oxybutynin Chloride ErOxybutynin Chloride50$1,156
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst52$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$121$71,50384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Litchfield Park

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →